1
|
Marnat G, Finistis S, Delvoye F, Sibon I, Desilles JP, Mazighi M, Gariel F, Consoli A, Rosso C, Clarençon F, Elhorany M, Denier C, Chalumeau V, Caroff J, Veunac L, Bourdain F, Darcourt J, Olivot JM, Bourcier R, Dargazanli C, Arquizan C, Richard S, Lapergue B, Gory B. Safety and Efficacy of Cangrelor in Acute Stroke Treated with Mechanical Thrombectomy: Endovascular Treatment of Ischemic Stroke Registry and Meta-analysis. AJNR Am J Neuroradiol 2022; 43:410-415. [PMID: 35241418 PMCID: PMC8910798 DOI: 10.3174/ajnr.a7430] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Accepted: 12/23/2021] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Rescue therapies are increasingly used in the setting of endovascular therapy for large-vessel occlusion strokes. Among these, cangrelor, a new P2Y12 inhibitor, offers promising pharmacologic properties to join the reperfusion strategies in acute stroke. We assessed the safety and efficacy profiles of cangrelor combined with endovascular therapy in patients with large-vessel-occlusion stroke. MATERIALS AND METHODS We performed a retrospective patient data analysis in the ongoing prospective multicenter observational Endovascular Treatment in Ischemic Stroke Registry in France from July 2018 to December 2020 and conducted a systematic review and meta-analysis using several data bases. Indications for cangrelor administration were rescue strategy in case of refractory intracranial occlusion with or without intracranial rescue stent placement, and cervical carotid artery stent placement in case of cervical occlusion (tandem occlusion or isolated cervical carotid occlusion). RESULTS In the clinical registry, 44 patients were included (median initial NIHSS score, 12; prior intravenous thrombolysis, 29.5%). Intracranial stent placement was performed in 54.5% (n = 24/44), and cervical stent placement, in 27.3% (n = 12/44). Adjunctive aspirin and heparin were administered in 75% (n = 33/44) and 40.9% (n = 18/44), respectively. Rates of symptomatic intracerebral hemorrhage, parenchymal hematoma, and 90-day mortality were 9.5% (n = 4/42), 9.5% (n = 4/42), and 24.4% (n = 10/41). Favorable outcome (90-day mRS, 0-2) was reached in 51.2% (n = 21/41), and successful reperfusion, in 90.9% (n = 40/44). The literature search identified 6 studies involving a total of 171 subjects. In the meta-analysis, including our series data, symptomatic intracerebral hemorrhage occurred in 8.6% of patients (95% CI, 5.0%-14.3%) and favorable outcome was reached in 47.6% of patients (95% CI, 27.4%-68.7%). The 90-day mortality rate was 22.6% (95% CI, 13.6%-35.2%). Day 1 artery patency was observed in 89.7% (95% CI, 81.4%-94.6%). CONCLUSIONS Cangrelor offers promising safety and efficacy profiles, especially considering the complex endovascular reperfusion procedures in which it is usually applied. Further large prospective data are required to confirm these findings.
Collapse
Affiliation(s)
- G. Marnat
- From the Department of Diagnostic and Interventional Neuroradiology (G.M., F.G.), University Hospital of Bordeaux, Bordeaux, France
| | - S. Finistis
- Aristotle University of Thessaloniki (S.F.), AhepaHospital, Thessaloniki, Greece
| | - F. Delvoye
- Department of Interventional Neuroradiology (F.D., J.-P.D., M.M.), Rothschild Foundation, Paris, France
| | - I. Sibon
- Department of Neurology (I.S.), Stroke Center, University Hospital of Bordeaux, Bordeaux, France
| | - J.-P. Desilles
- Department of Interventional Neuroradiology (F.D., J.-P.D., M.M.), Rothschild Foundation, Paris, France
| | - M. Mazighi
- Department of Interventional Neuroradiology (F.D., J.-P.D., M.M.), Rothschild Foundation, Paris, France
| | - F. Gariel
- From the Department of Diagnostic and Interventional Neuroradiology (G.M., F.G.), University Hospital of Bordeaux, Bordeaux, France
| | - A. Consoli
- Department of Diagnostic and Interventional Neuroradiology (A.C.), Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France
| | | | - F. Clarençon
- Neuroradiology (F.C., M.E.), Centre Hospitalier Universitaire Pitié Salpétrière Hospital, Paris, France
| | - M. Elhorany
- Neuroradiology (F.C., M.E.), Centre Hospitalier Universitaire Pitié Salpétrière Hospital, Paris, France
| | | | - V. Chalumeau
- Neuroradiolology (V.C., J.C.) Centre Hospitalier Universitaire Kremlin Bicêtre, Le Kremlin Bicêtre, France
| | - J. Caroff
- Neuroradiolology (V.C., J.C.) Centre Hospitalier Universitaire Kremlin Bicêtre, Le Kremlin Bicêtre, France
| | - L. Veunac
- Neuroradiolology (L.V.), Centre Hospitalier Cõte Basque, Bayonne, France
| | | | - J. Darcourt
- Neuroradiolology (J.D.), Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | | | - R. Bourcier
- Department of Neuroradiology (R.B.), University Hospital of Nantes, Nantes, France
| | - C. Dargazanli
- Departments of Interventional Neuroradiology (C. Dargazanli)
| | - C. Arquizan
- Neurology (C.A.), Centre Hospitalier Regional Universitaire Gui de Chauliac, Montpellier, France
| | - S. Richard
- Department of Neurology (S.R.), Université de Lorraine, Centre Hospitalier Regional Universitaire Nancy, Nancy, France
| | - B. Lapergue
- Department of Neurology (B.L.), Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France
| | - B. Gory
- Department of Diagnostic and Therapeutic Neuroradiology (B.G.), Université de Lorraine, Centre Hospitalier Regional Universitaire Nancy, Nancy, France,Université de Lorraine (B.G.), Imagerie Adaptative Diagnostique et Interventionnelle, Institut National de la Santé et de la Recherche Médicale U1254, Nancy, France
| |
Collapse
|
2
|
Legris N, Sarov M, Chassin O, Hascoët S, Gerardin B, Denier C. Patent Foramen Ovale closure in adolescent stroke patients. Rev Neurol (Paris) 2021; 177:1200-1201. [PMID: 34412889 DOI: 10.1016/j.neurol.2020.12.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Revised: 12/21/2020] [Accepted: 12/29/2020] [Indexed: 10/20/2022]
Affiliation(s)
- N Legris
- Stroke Unit, Department of Neurology, Hôpital Bicêtre, Université Paris Saclay, Le Kremlin Bicêtre, Assistance Publique - Hôpitaux de Paris (AP-HP), 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France.
| | - M Sarov
- Stroke Unit, Department of Neurology, Hôpital Bicêtre, Université Paris Saclay, Le Kremlin Bicêtre, Assistance Publique - Hôpitaux de Paris (AP-HP), 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France
| | - O Chassin
- Stroke Unit, Department of Neurology, Hôpital Bicêtre, Université Paris Saclay, Le Kremlin Bicêtre, Assistance Publique - Hôpitaux de Paris (AP-HP), 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France
| | - S Hascoët
- Department of Cardiology, Centre Chirurgical Marie Lannelongue, 133, avenue de la Résistance, 92350 Le Plessis-Robinson, France
| | - B Gerardin
- Department of Cardiology, Centre Chirurgical Marie Lannelongue, 133, avenue de la Résistance, 92350 Le Plessis-Robinson, France
| | - C Denier
- Stroke Unit, Department of Neurology, Hôpital Bicêtre, Université Paris Saclay, Le Kremlin Bicêtre, Assistance Publique - Hôpitaux de Paris (AP-HP), 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France
| |
Collapse
|
3
|
Quirins M, Petrescu AM, Masnou P, Bouilleret V, Denier C. Systematic prolonged video-electroencephalograms identify electrographic seizures in 5% of acute stroke patients with aphasia. Rev Neurol (Paris) 2021; 177:1001-1005. [PMID: 33483091 DOI: 10.1016/j.neurol.2020.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Revised: 09/03/2020] [Accepted: 10/16/2020] [Indexed: 11/26/2022]
Abstract
In stroke units, diagnosing seizures may be difficult, especially in aphasic patients. We discuss herein our systematic 4-hour video EEG monitoring of 61 patients with aphasia within the first 72hours after the onset of ischaemic stroke. Five electrographic seizures were identified in 3 patients, with no clinical signs apparent on the video and no symptoms reported by patients. We did not record status epilepticus nor generalized seizure. Comparative analyses disclosed a higher risk of early seizures in patients with haemorrhagic transformation. Video EEG monitoring detected electrographic seizures in 5% of stroke patients with aphasia. This monitoring could be useful for selected patients, especially those with haemorrhagic transformation.
Collapse
Affiliation(s)
- M Quirins
- Departments of Neurology (MQ, PM, CD) and Neurophysiology (AP, VB), Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 94275 Le Kremlin-Bicêtre, France.
| | - A M Petrescu
- Departments of Neurology (MQ, PM, CD) and Neurophysiology (AP, VB), Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 94275 Le Kremlin-Bicêtre, France
| | - P Masnou
- Departments of Neurology (MQ, PM, CD) and Neurophysiology (AP, VB), Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 94275 Le Kremlin-Bicêtre, France
| | - V Bouilleret
- Departments of Neurology (MQ, PM, CD) and Neurophysiology (AP, VB), Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 94275 Le Kremlin-Bicêtre, France
| | - C Denier
- Departments of Neurology (MQ, PM, CD) and Neurophysiology (AP, VB), Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 94275 Le Kremlin-Bicêtre, France
| |
Collapse
|
4
|
Tennenbaum J, Groh M, Venditti L, Campos Gazeau F, Chalayer E, Hamidou M, Hunault M, Lyoubi A, Muron T, Sene D, Slama B, Lefèvre G, Kahn J, Denier C, Rohmer J. Incidence et caractéristiques des AVC ischémiques au cours des Syndromes Hyperéosinophiliques clonaux: toxicité vasculaire des éosinophiles? Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Boulenoir N, Turc G, Henon H, Laksiri N, Mounier-Véhier F, Girard Buttaz I, Duong DL, Papassin J, Yger M, Triquenot A, Lyoubi A, Ter Schiphorst A, Denier C, Baron JC, Seners P. Early neurological deterioration following thrombolysis for minor stroke with isolated internal carotid artery occlusion. Eur J Neurol 2020; 28:479-490. [PMID: 32959480 DOI: 10.1111/ene.14541] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Accepted: 09/09/2020] [Indexed: 01/21/2023]
Abstract
BACKGROUND AND PURPOSE Better understanding the incidence, predictors and mechanisms of early neurological deterioration (END) following intravenous thrombolysis (IVT) for acute stroke with mild symptoms and isolated internal carotid artery occlusion (iICAo) may inform therapeutic decisions. METHODS From a multicenter retrospective database, we extracted all patients with both National Institutes of Health Stroke Scale (NIHSS) score <6 and iICAo (i.e. not involving the Willis circle) on admission imaging, intended for IVT alone. END was defined as ≥4 NIHSS points increase within 24 h. END and no-END patients were compared for (i) pre-treatment clinical and imaging variables and (ii) occurrence of intracranial occlusion, carotid recanalization and parenchymal hemorrhage on follow-up imaging. RESULTS Seventy-four patients were included, amongst whom 22 (30%) patients experienced END. Amongst pre-treatment variables, suprabulbar carotid occlusion was the only admission predictor of END following stepwise variable selection (odds ratio = 4.0, 95% confidence interval: 1.3-12.2; P = 0.015). On follow-up imaging, there was no instance of parenchymal hemorrhage, but an intracranial occlusion was now present in 76% vs. 0% of END and no-END patients, respectively (P < 0.001), and there was a trend toward higher carotid recanalization rate in END patients (29% vs. 9%, P = 0.07). As compared to no-END, END was strongly associated with a poor 3-month outcome. CONCLUSIONS Early neurological deterioration is a frequent and highly deleterious event after IVT for minor stroke with iICAo, and is of thromboembolic origin in three out of four patients. The strong association with iICAo site-largely a function of underlying stroke etiology-may point to a different response of the thrombus to IVT. These findings suggest END may be preventable in this setting.
Collapse
Affiliation(s)
- N Boulenoir
- Neurology Department, GHU Paris Psychiatrie et Neurosciences, Sainte-Anne Hospital, INSERM UMR 1266, FHU NeuroVasc, Université de Paris, Paris, France
| | - G Turc
- Neurology Department, GHU Paris Psychiatrie et Neurosciences, Sainte-Anne Hospital, INSERM UMR 1266, FHU NeuroVasc, Université de Paris, Paris, France
| | - H Henon
- Inserm U1171, Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Université de Lille, Lille, France
| | - N Laksiri
- Neurology Department, La Timone University Hospital, Marseille, France
| | | | - I Girard Buttaz
- Neurology Department, Valenciennes Hospital, Valenciennes, France
| | - D-L Duong
- Neurology Department, Versailles University Hospital, Versailles, France
| | - J Papassin
- Stroke Unit, Grenoble University Hospital, Grenoble, France.,Neurology Department, Chambery Hospital, Chambery, France
| | - M Yger
- Neurology Department, Saint-Antoine Hospital, Paris, France
| | - A Triquenot
- Neurology Department, Rouen Hospital, Rouen, France
| | - A Lyoubi
- Neurology Department, Delafontaine Hospital, St. Denis, France
| | | | - C Denier
- Neurology Department, CHU Kremlin Bicêtre, Kremlin Bicêtre, France
| | - J-C Baron
- Neurology Department, GHU Paris Psychiatrie et Neurosciences, Sainte-Anne Hospital, INSERM UMR 1266, FHU NeuroVasc, Université de Paris, Paris, France
| | - P Seners
- Neurology Department, GHU Paris Psychiatrie et Neurosciences, Sainte-Anne Hospital, INSERM UMR 1266, FHU NeuroVasc, Université de Paris, Paris, France
| | | |
Collapse
|
6
|
Lapergue B, Lyoubi A, Meseguer E, Avram I, Denier C, Venditti L, Consoli A, Guedon A, Houdart E, Weisenburger-Lile D, Piotin M, Maier B, Obadia M, Broucker TDE. Large vessel stroke in six patients following SARS-CoV-2 infection: a retrospective case study series of acute thrombotic complications on stable underlying atherosclerotic disease. Eur J Neurol 2020; 27:2308-2311. [PMID: 32761999 PMCID: PMC7436672 DOI: 10.1111/ene.14466] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Accepted: 08/01/2020] [Indexed: 12/11/2022]
Abstract
Background and purpose Ischaemic stroke has been described in association with COVID‐19. Several pathophysiological mechanisms have been suggested, i.e. prothrombotic state, cardiac injury etc. It was sought to assess the potential association between ischaemic stroke associated with SARS‐CoV‐2 infection and underlying atherosclerotic lesions. Methods A retrospective analysis of stroke related to large vessel occlusion was conducted amongst patients with SARS‐CoV‐2 infection and underlying mild atherosclerotic disease, between 19 March and 19 April 2020 in six different stroke centers in the Île‐de France area, France. Results The median age was 52 years, median body mass index was 29.5 kg/m2. All patients displayed previous vascular risk factors such as high blood pressure, diabetes, dyslipidemia or body mass index > 25. The delay between the first respiratory symptoms of COVID‐19 and stroke was 11.5 days. At baseline, all had tandem occlusions, i.e. intracerebral and extracerebral thrombus assessed with computed tomography or magnetic resonance imaging. Cases displayed a large thrombus in the cervical carotid artery with underlying mild non‐stenosing atheroma, after an etiological workup based on angio‐computed tomography or magnetic resonance imaging and/or cervical echography. Conclusion Our study should alert clinicians to scrutinize any new onset of ischaemic stroke during COVID‐19 infection, mainly in patients with vascular risk factors or underlying atherosclerotic lesions.
Collapse
Affiliation(s)
- B Lapergue
- Neurovascular Unit, Interventional Neuroradiology Department, Foch Hospital, Suresnes, France
| | - A Lyoubi
- Neurovascular Unit, Saint Denis Hospital, Paris, France
| | - E Meseguer
- Neurovascular Unit, Bichat University Hospital, Paris, France
| | - I Avram
- Neurovascular Unit, Bichat University Hospital, Paris, France
| | - C Denier
- Neurovascular Unit, Interventional Neuroradiology Department, Kremlin-Bicetre University Hospital, Kremlin-Bicetre, France
| | - L Venditti
- Neurovascular Unit, Interventional Neuroradiology Department, Kremlin-Bicetre University Hospital, Kremlin-Bicetre, France
| | - A Consoli
- Neurovascular Unit, Interventional Neuroradiology Department, Foch Hospital, Suresnes, France
| | - A Guedon
- Neurovascular Unit, Interventional Neuroradiology Department, Lariboisiere University Hospital Paris, Paris, France
| | - E Houdart
- Neurovascular Unit, Interventional Neuroradiology Department, Lariboisiere University Hospital Paris, Paris, France
| | - D Weisenburger-Lile
- Neurovascular Unit, Interventional Neuroradiology Department, Foch Hospital, Suresnes, France
| | - M Piotin
- Interventional Neuroradiology Department Rothschild Fundation, Paris, France
| | - B Maier
- Interventional Neuroradiology Department Rothschild Fundation, Paris, France
| | - M Obadia
- Interventional Neuroradiology Department Rothschild Fundation, Paris, France
| | | |
Collapse
|
7
|
Osman O, Labrune P, Reiner P, Sarov M, Nasser G, Riant F, Tournier-lasserve E, Chabriat H, Denier C. Leukoencephalopathy with calcifications and cysts (LCC): 5 cases and literature review. Rev Neurol (Paris) 2020; 176:170-179. [DOI: 10.1016/j.neurol.2019.06.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Revised: 06/03/2019] [Accepted: 06/04/2019] [Indexed: 11/25/2022]
|
8
|
Quirins M, Dussaule C, Denier C, Masnou P. Epilepsy after stroke: Definitions, problems and a practical approach for clinicians. Rev Neurol (Paris) 2018; 175:126-132. [PMID: 30415978 DOI: 10.1016/j.neurol.2018.02.088] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Accepted: 02/28/2018] [Indexed: 11/17/2022]
Abstract
Stroke, whether ischemic or hemorrhagic, is the main etiology of epilepsy in the elderly. However, incidences and outcomes differ according to stroke subtype and delay of onset following the stroke. While the medical literature is extensive, it is not always consistent, and many questions still remain regarding risk factors and management of vascular epilepsy. Thus, the present report here is an overview of the clinical aspects of vascular epilepsy using a practical approach that integrates data from meta-analyses and the more recently published expert recommendations.
Collapse
Affiliation(s)
- M Quirins
- Service de neurologie adulte, CHU Bicêtre, 78, avenue du Général Leclerc, 94270 Le Kremlin Bicêtre, France.
| | - C Dussaule
- Service de neurologie adulte, CHU Bicêtre, 78, avenue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
| | - C Denier
- Service de neurologie adulte, CHU Bicêtre, 78, avenue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
| | - P Masnou
- Service de neurologie adulte, CHU Bicêtre, 78, avenue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
| |
Collapse
|
9
|
Laurent J, Mas R, Creppy L, Frank M, Letiec C, Denier C. Comparaison de deux bases de données pour la fiabilisation du décompte des thrombolyses intraveineuses dans la prise en charge des accidents vasculaires cérébraux ischémiques à l’hôpital de Bicêtre, France. Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.01.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
10
|
Bacquet JL, Sarov-Rivière M, Denier C, Querques G, Riou B, Bonin L, Barreau E, Labetoulle M, Rousseau A. Fundus autofluorescence in retinal artery occlusion: A more precise diagnosis. J Fr Ophtalmol 2017; 40:648-653. [PMID: 28882392 DOI: 10.1016/j.jfo.2017.03.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Revised: 03/08/2017] [Accepted: 03/09/2017] [Indexed: 11/18/2022]
Abstract
IMPORTANCE Retinal artery occlusion (RAO) is a medical emergency associated with a high risk of cerebral vascular accident and other cardiovascular events. Among patients with non-arteritic RAO, a retinal embolus is observed in approximately 40% of cases. Fundus examination and retinography are not reliable to predict the nature of the emboli. OBSERVATIONS We report three consecutive cases of central and branch RAO that were investigated with fundus autofluorescence, fluorescein angiography and color retinal photographs. All patients underwent complete neurological and cardiovascular workups, with brain imaging, cardiac Doppler ultrasound, carotid Dopplers and Holter ECG's, to determine the underlying mechanism of retinal embolism. In the three cases, aged 77.7±4 years (2 women and 1 man), fundus autofluorescence demonstrated hyperautofluorescent emboli. In two cases, it allowed visualization of emboli that were not detected with fundus examination or retinography. The cardiovascular work-up demonstrated atheromatous carotid or aortic plaques in all patients. In one case, it permitted the diagnosis of RAO. Two of the three cases were considered to be of atherosclerotic origin and one of undefined origin. CONCLUSION AND RELEVANCE Fundus autofluorescence may help to detect and characterize retinal emboli. Since lipofuscin, which is present in large quantity in atherosclerotic plaques, is the main fluorophore detected with fundus autofluorescence, this non-invasive and simple examination may give information about the underlying mechanism of retinal embolism, and thus impact the etiologic assessment of RAO. Additional studies are necessary to confirm this potential role of autofluorescence.
Collapse
Affiliation(s)
- J-L Bacquet
- Service d'ophtalmologie, hôpital Bicêtre, université Paris-Sud, DHU vision et handicaps, Assistance publique-Hôpitaux de Paris, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France
| | - M Sarov-Rivière
- Service de neurologie, hôpital Bicêtre, université Paris-Sud, Assistance publique-Hôpitaux de Paris, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France
| | - C Denier
- Service de neurologie, hôpital Bicêtre, université Paris-Sud, Assistance publique-Hôpitaux de Paris, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France
| | - G Querques
- Service d'ophtalmologie, centre hospitalier intercommunal de Créteil, université Paris-Est, DHU vision et handicaps, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France
| | - B Riou
- Service d'ophtalmologie, hôpital Bicêtre, université Paris-Sud, DHU vision et handicaps, Assistance publique-Hôpitaux de Paris, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France
| | - L Bonin
- Service d'ophtalmologie, hôpital Bicêtre, université Paris-Sud, DHU vision et handicaps, Assistance publique-Hôpitaux de Paris, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France
| | - E Barreau
- Service d'ophtalmologie, hôpital Bicêtre, université Paris-Sud, DHU vision et handicaps, Assistance publique-Hôpitaux de Paris, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France
| | - M Labetoulle
- Service d'ophtalmologie, hôpital Bicêtre, université Paris-Sud, DHU vision et handicaps, Assistance publique-Hôpitaux de Paris, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France
| | - A Rousseau
- Service d'ophtalmologie, hôpital Bicêtre, université Paris-Sud, DHU vision et handicaps, Assistance publique-Hôpitaux de Paris, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France.
| |
Collapse
|
11
|
Martin G, Brousse V, De Montalembert M, Albuisson E, Grevent D, Denier C, Michel S, Abadie V, Chalumeau M, Boddaert N, Bremond-Gignac D, Robert M. New insights on the anatomy and function of the retina in sickle cell disease. Acta Ophthalmol 2017. [DOI: 10.1111/j.1755-3768.2017.02364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- G.C. Martin
- Ophthalmology; Necker-Enfants Malades- APHP; Paris France
| | - V. Brousse
- Paediatry; Necker-Enfants Malades- APHP; Paris France
| | | | | | - D. Grevent
- Radiology; Necker-Enfants Malades- APHP; Paris France
| | - C. Denier
- Ophthalmology; Necker-Enfants Malades- APHP; Paris France
| | - S. Michel
- Ophthalmology; Necker-Enfants Malades- APHP; Paris France
| | - V. Abadie
- Paediatry; Necker-Enfants Malades- APHP; Paris France
| | - M. Chalumeau
- Paediatry; Necker-Enfants Malades- APHP; Paris France
| | - N. Boddaert
- Radiology; Necker-Enfants Malades- APHP; Paris France
| | | | - M.P. Robert
- Ophthalmology; Necker-Enfants Malades- APHP; Paris France
| |
Collapse
|
12
|
Denier C, Robert M, Adjadj E, Michel S, Aymard P, Bremond-Gignac D. Presentation and management of cytomegalovirus retinitis in immunocompromised children. Acta Ophthalmol 2016. [DOI: 10.1111/j.1755-3768.2016.0622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Denier C, Chassin O, Vandendries C, Bayon de la Tour L, Cauquil C, Sarov M, Adams D, Flamand-Roze C. Thrombolysis in Stroke Patients with Isolated Aphasia. Cerebrovasc Dis 2016; 41:163-9. [PMID: 26751564 DOI: 10.1159/000442303] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Accepted: 11/06/2015] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Data about evolution of aphasia following stroke are rare and controversial especially following fibrinolysis. The aim of this study was to describe the early clinical patterns of isolated aphasia in consecutive stroke patients with or without thrombolysis. METHODS Clinical and radiological data of consecutive stroke patients were routinely entered in prospective registry. Patients were considered aphasic when NIHSS (National Institutes of Health Stroke Scale) item 9 >0. 'Isolated aphasia' was defined by aphasic patients without motor limb deficit. We created a 'composite language score' obtained by summing the NIHSS items 1b, 1c and 9, which reflects language-processing ability. Recovery of functions was evaluated as measured by global NIHSS, composite language score and language screening test (LAST) at baseline, H24 and day 7 (D7). 'Mild deficit' was defined as global NIHSS <5. RESULTS A total of 100 consecutive patients met study criteria for isolated aphasia. Twenty-five underwent thrombolysis and 75 did not. There was no difference between the 2 groups concerning demographic characteristics, involved territories and presence of arterial occlusion, initial median NIHSS, composite language and LAST scores at entrance. Evolution was significantly better in thrombolysed patient for the 3 testings: NIHSS, composite language score and LAST at D7 (respective p = 0.0002; p = 0.01 and p = 0.004). Similar results were found when we focused on the subgroups of patients with initial 'mild' deficits (p = 0.01; p = 0.0003 and p = 0.007). No symptomatic hemorrhagic transformation occurred following thrombolysis. CONCLUSION These data strongly suggest that thrombolysis is safe and effective in patients with 'isolated aphasia,' even if the global NIHSS score is <5.
Collapse
Affiliation(s)
- C Denier
- Department of Neurology and Stroke Center, Paris-Sud University, Le Kremlin-Bicx00EA;tre, France
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Bourgeois-Marcotte J, Flamand-Roze C, Denier C, Monetta L. [LAST-Q: Adaptation and normalisation in Quebec of the Language Screening Test]. Rev Neurol (Paris) 2015; 171:433-6. [PMID: 25917163 DOI: 10.1016/j.neurol.2015.03.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2014] [Revised: 01/20/2015] [Accepted: 03/02/2015] [Indexed: 10/23/2022]
Abstract
The goal of the present study was to adapt and to establish normative data for the recently developed Language Screening Test (LAST; Flamand-Roze et al., 2011) in the French-Canadian population according to age and level of education. After an adaptation process, 100 French-Canadian speakers were evaluated with the LAST-Q. As expected, a perfect score of 15/15 was obtained for all high level education participants, and a score of 14/15 was obtained for all participants with a lowest level of education or aged 80 years or more. Thanks to this adaptation, LAST-Q can be used in acute patients in stroke unit in Quebec.
Collapse
Affiliation(s)
- J Bourgeois-Marcotte
- Département de réadaptation, faculté de médecine, université Laval, 1050, avenue de la Médecine, Québec, G1V 0A6, Canada
| | - C Flamand-Roze
- CHU de Bicêtre, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France
| | - C Denier
- Faculté de médecine Paris Sud, hôpital de Bicêtre, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre cedex, France
| | - L Monetta
- Département de réadaptation, faculté de médecine, université Laval, 1050, avenue de la Médecine, Québec, G1V 0A6, Canada; Centre de recherche de l'institut universitaire en santé mentale de Québec (CRIUSMQ), 2601, de la Canardière, Québec, G1J 2G3, Canada.
| |
Collapse
|
15
|
Rerat K, Parker F, Nasser G, Vidaud D, Riant F, Tournier-Lasserve E, Denier C. Occurrence of multiple Cerebral Cavernous Malformations in a patient with Neurofibromatosis type 1. J Neurol Sci 2015; 350:98-100. [PMID: 25702150 DOI: 10.1016/j.jns.2015.02.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2014] [Revised: 02/08/2015] [Accepted: 02/10/2015] [Indexed: 11/27/2022]
Abstract
BACKGROUND Neurofibromatosis 1 (NF1) belongs to the autosomal dominant neurocutaneous disorders' group, which mainly includes NF1 and NF2, tuberous sclerosis, von Hippel-Lindau disease and Cerebral Cavernous Malformations (CCMs). NF1 has a major impact on the nervous system, eye, skin, bone or cardiovascular system. Cerebrovascular lesions have been reported in NF1 including aneurysm, pseudoaneurysm, arteriovenous malformations, vascular stenosis or occlusion and Moya moya syndrome. OBJECTIVE To report a case of an NF1 patient with multiple CCMs. OBSERVATION A 47-year-old man with café-au-lait skin lesions, countless cutaneous neurofibromas, short stature and scoliosis was admitted for progressive spinal cord compression due to histologically proven neurofibroma. Systematic cerebral MRI screening including gradient echo sequences showed multiple asymptomatic CCMs. Screening of CCM1, CCM2 and CCM3 genes was negative while a deleterious frameshift mutation was identified in NF1 gene. CONCLUSION While single CCM can occur in NF1 patients following radiation exposure, they are only rarely reported in non-irradiated NF1 brain. Even if it could be a fortuitous association, plausible links and explanations exist. If cerebral MRI can be systematic in NF1 to detect asymptomatic gliomas, used protocols in neuroradiology do not usually include gradient echo sequences, the most sensitive test for CCM detection, leading possibly to failure to detect these vascular lesions. More reports having this combination and further investigations of NF1 families will certainly provide a better understanding of links between these 2 phakomatoses, as recently reported with "multiple meningiomas" phenotype associated with multiple CCMs in patients with CCM3 gene mutations or café-au-lait skin lesions in CCM1 mutation carriers.
Collapse
Affiliation(s)
- K Rerat
- Department of Neurology, Université Paris Sud, Faculté de Médecine Paris Sud, Hôpital de Bicêtre, Assistance Publique, Hôpitaux de Paris (AP-HP), France; Department of Neurosurgery, Université Paris Sud, Faculté de Médecine Paris Sud, Hôpital de Bicêtre, Assistance Publique, Hôpitaux de Paris (AP-HP), France
| | - F Parker
- Department of Neurosurgery, Université Paris Sud, Faculté de Médecine Paris Sud, Hôpital de Bicêtre, Assistance Publique, Hôpitaux de Paris (AP-HP), France
| | - G Nasser
- Department of NeuroRadiology, Université Paris Sud, Faculté de Médecine Paris Sud, Hôpital de Bicêtre, Assistance Publique, Hôpitaux de Paris (AP-HP), France
| | - D Vidaud
- INSERM UMR745, Paris Descartes University, France
| | - F Riant
- AP-HP, Service de Génétique, Hôpital Lariboisière, France; INSERM UMR 1161, Paris Diderot University, France
| | - E Tournier-Lasserve
- AP-HP, Service de Génétique, Hôpital Lariboisière, France; INSERM UMR 1161, Paris Diderot University, France
| | - C Denier
- Department of Neurology, Université Paris Sud, Faculté de Médecine Paris Sud, Hôpital de Bicêtre, Assistance Publique, Hôpitaux de Paris (AP-HP), France.
| |
Collapse
|
16
|
Apoil M, Parienti JJ, Labreuche J, Mazighi M, Pico F, Denier C, Touze E. Facteurs prédictifs de réponse précoce (24heures) à la thrombolyse intraveineuse à la phase aiguë d’un infarctus cérébral : revue systématique avec méta-analyse et validation sur données originales. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Flamand-Roze C, Bayon De La Tour L, Sarov M, Yeung J, Falissard B, Pico F, Denier C. Aphasie et troubles moteurs dans les AVC : quelle évolution précoce en suite de thrombolyse ? Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Bayon De La Tour L, Sarov M, Flamand-Roze C, Denier C. Aphasies isolées et thrombolyses. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
19
|
Depuydt S, Sarov M, Vandendries C, Guedj T, Cauquil C, Assayag P, Lambotte O, Ducreux D, Denier C. Significance of acute multiple infarcts in multiple cerebral circulations on initial diffusion weighted imaging in stroke patients. J Neurol Sci 2014; 337:151-5. [DOI: 10.1016/j.jns.2013.11.039] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Revised: 11/20/2013] [Accepted: 11/25/2013] [Indexed: 11/26/2022]
|
20
|
Riant F, Bergametti F, Fournier HD, Chapon F, Michalak-Provost S, Cecillon M, Lejeune P, Hosseini H, Choe C, Orth M, Bernreuther C, Boulday G, Denier C, Labauge P, Tournier-Lasserve E. CCM3 Mutations Are Associated with Early-Onset Cerebral Hemorrhage and Multiple Meningiomas. Mol Syndromol 2013; 4:165-72. [PMID: 23801932 DOI: 10.1159/000350042] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/11/2013] [Indexed: 11/19/2022] Open
Abstract
Mutations of CCM3/PDCD10 cause 10-15% of hereditary cerebral cavernous malformations. The phenotypic characterization of CCM3-mutated patients has been hampered by the limited number of patients harboring a mutation in this gene. This is the first report on molecular and clinical features of a large cohort of CCM3 patients. Molecular screening for point mutations and deletions was used to identify 54 CCM3-mutated index patients. Age at referral and clinical onset, type of inaugural events and presence of extra-axial lesions were investigated in these 54 index patients and 22 of their mutated relatives. Mean age at clinical onset was 23.0 ± 16 years. Clinical onset occurred before 10 years in 26% of the patients, and cerebral hemorrhage was the initial presentation in 72% of these patients. Multiple extra-axial, dural-based lesions were detected in 7 unrelated patients. These lesions proved to be meningiomas in 3 patients who underwent neurosurgery and pathological examination. This 'multiple meningiomas' phenotype is not associated with a specific CCM3 mutation. Hence, CCM3 mutations are associated with a high risk of early-onset cerebral hemorrhage and with the presence of multiple meningiomas.
Collapse
Affiliation(s)
- F Riant
- Service de Génétique Neuro-Vasculaire, Assistance Publique-Hôpitaux de Paris, Paris, France ; Centre de Référence des Maladies Vasculaires Rares du Cerveau et de L'Œil, Groupe Hospitalier Lariboisière - Fernand Widal, Paris, France ; Unité Mixte de Recherche-S-740, Institut National de la Santé et de la Recherche Médicale, Paris, France ; Unité Mixte de Recherche-S-740, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Sabben C, Cauquil C, Denier C, Adams D, Théaudin M. Impact psychologique de l’annonce d’une sérologie positive JC chez les patients traités par Tysabri®. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
Flowers H, Flamand-Roze C, Roze E, Skoretz S, Sénal C, Denier C, Martino R. Adapter une échelle de langage (LAST : language screening test) du français à l’anglais : un challenge ! Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Flamand-Roze C, Sarov M, Depuydt S, Roze E, Denier C. Thrombolyse et aphasie isolée : au-delà du score NIHSS. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Beaudonnet G, Denier C, Lacroix C, Slama A, Adams D. Les neuropathies des mitochondriopathies : étude de 18 cas et revue de la littérature. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Ratour C, Michot JM, Seta V, Denis D, Fourn E, Denier C, Rocher L, Teicher E, Guillevin L, Lambotte O. Un cas inhabituel de périartérite noueuse avec atteinte des vaisseaux du cou et des artères pulmonaires. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.10.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
26
|
Cauquil C, Souillard-Scemama R, Labetoulle M, Adams D, Ducreux D, Denier C. Diffusion MRI and tensor tractography in ischemic optic neuropathy. Acta Neurol Belg 2012; 112:209-11. [PMID: 22426658 DOI: 10.1007/s13760-012-0013-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2011] [Accepted: 08/25/2011] [Indexed: 11/29/2022]
Abstract
Ischemic optic neuropathies (IONs) are among the most prevalent diseases causing visual impairment in middle-aged and elderly people. While arteritic ION is an ocular emergency and requires early diagnosis and immediate treatment with systemic high-dose corticosteroids to prevent further visual loss, treatment options for non-arteritic ION remain limited. We describe the case of a woman with unilateral right-sided non-arteritic posterior ischemic optic neuropathy. The diagnosis was made on clinical and radiographic grounds. Diffusion-weighted sequences and apparent diffusion coefficient maps revealed markedly restricted diffusion in the right optic nerve. It was very helpful to precise the posterior topography of the optic nerve lesion. Furthermore, we reported the diffusion tensor tractography study which appears to be an objective tool to assess the incomplete visual recovery. These MRI techniques including tensor tractography remain to be evaluated in large cohort of ION patients' particularly in future therapeutic trials.
Collapse
Affiliation(s)
- C Cauquil
- Department of Neurology, Centre Hospitalo-Universitaire de Bicêtre, Assistance Publique-Hôpitaux de Paris, 78 rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex, France
| | | | | | | | | | | |
Collapse
|
27
|
Flamand-Roze C, Roze E, Denier C. Troubles du langage et de la déglutition à la phase aiguë des accidents vasculaires cérébraux : outils d’évaluation et intérêt d’une prise en charge précoce. Rev Neurol (Paris) 2012; 168:415-24. [DOI: 10.1016/j.neurol.2011.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2011] [Revised: 10/10/2011] [Accepted: 10/12/2011] [Indexed: 10/28/2022]
|
28
|
|
29
|
Melki E, Denier C, Théaudin-Saliou M, Sachet M, Ducreux D, Saliou G. External carotid artery branches involvement in reversible cerebral vasoconstriction syndrome. J Neurol Sci 2012; 313:46-7. [DOI: 10.1016/j.jns.2011.09.033] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2011] [Revised: 09/22/2011] [Accepted: 09/27/2011] [Indexed: 10/16/2022]
|
30
|
Adams D, Lacroix C, Antonini T, Lozeron P, Denier C, Kreib AM, Epelbaum S, Blandin F, Karam V, Azoulay D, Adam R, Castaing D, Samuel D. Symptomatic and proven de novo amyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients. Amyloid 2011; 18 Suppl 1:174-7. [PMID: 21838477 DOI: 10.3109/13506129.2011.574354065] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- D Adams
- French Reference Center for FAP, Université Paris Sud, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Adams D, Lozeron P, Theaudin M, Denier C, Fagniez O, Rerat K, Signate A, Corcia P, Lacroix C. Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients. Amyloid 2011; 18 Suppl 1:98-100. [PMID: 21838448 DOI: 10.3109/13506129.2011.574354036] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- D Adams
- French Reference Center for FAP and Other Rare Peripheral Neuropathies NNERF, Université Paris Sud, Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Flamand-Roze C, Cauquil-Michon C, Roze E, Souillard-Scemama R, Maintigneux L, Ducreux D, Adams D, Denier C. Aphasia in border-zone infarcts has a specific initial pattern and good long-term prognosis. Eur J Neurol 2011; 18:1397-401. [PMID: 21554494 DOI: 10.1111/j.1468-1331.2011.03422.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND While border-zone infarcts (BZI) account for about 10% of strokes, studies on related aphasia are infrequent. The aim of this work was to redefine specifically their early clinical pattern and evolution. METHODS We prospectively studied consecutive patients referred to our stroke unit within a 2-year period. Cases of aphasia in right-handed patients associated with a MRI confirmed left-sided hemispheric BZI were included. These patients had a standardized language examination in the first 48 h, at discharge from stroke unit and between 6 and 18 months later. RESULTS Eight patients were included. Three had anterior (MCA/ACA), two posterior (MCA/PCA), two both anterior and posterior, and one bilateral BZI. All our patients initially presented transcortical mixed aphasia, characterized by comprehension and naming difficulties associated with preserved repetition. In all patients, aphasia rapidly improved. It fully recovered within a few days in three patients. Initial improvement was marked, although incomplete in the five remaining patients: their aphasias specifically evolved according to the stroke location toward transcortical motor aphasia for the three patients with anterior BZI and transcortical sensory aphasia for the two patients with posterior BZI. All patients made a full language recovery within 18 months after stroke. CONCLUSIONS We report a specific aphasic pattern associated with hemispheric BZI, including an excellent long-term outcome. These findings appear relevant to (i) clinically suspect BZI and (ii) plan rehabilitation and inform the patient and his family of likelihood of full language recovery.
Collapse
Affiliation(s)
- C Flamand-Roze
- Service de neurologie, CHU Bicêtre, AP-HP, Le Kremlin Bicêtre, France.
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Denier C, Guedj T, Dinanian S, Adams D. Brugada syndrome revealed by vertigo caused by cerebellar infarction. Eur J Neurol 2010; 17:e35-6. [DOI: 10.1111/j.1468-1331.2010.02978.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
34
|
Toulgoat F, Adams D, Nasser G, Ducreux D, Denier C. Intracerebral Hemorrhage Caused by Thrombosis of Developmental Venous Anomaly: Total Recovery following Anticoagulation. Eur Neurol 2010; 63:254-5. [PMID: 20375516 DOI: 10.1159/000277514] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2009] [Accepted: 01/11/2010] [Indexed: 11/19/2022]
Affiliation(s)
- F Toulgoat
- Department of Neuroradiology, Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, Le Kremlin-Bicêtre, France
| | | | | | | | | |
Collapse
|
35
|
Labauge P, Fontaine B, Neau JP, Bergametti F, Riant F, Blecon A, Marchelli F, Arnoult M, Lannuzel A, Clanet M, Olschwang S, Denier C, Tournier-Lasserve E. Multiple dural lesions mimicking meningiomas in patients with CCM3/PDCD10 mutations. Neurology 2009; 72:2044-6. [PMID: 19506228 DOI: 10.1212/wnl.0b013e3181a92b13] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- P Labauge
- Service de Neurologie, Hôpital Caremeau, CHU de Nimes, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Adams D, Lacroix C, Antonini T, Lozeron P, Denier C, Epelbaum S, Karam V, Blandin F, Azulay D, Adam R, Castaing D, Samuel D. Risque de neuropathie amyloïde à transthyrétine de novo après transplantation hépatique Domino de neuropathie amyloïde familiale (NAF). Rev Neurol (Paris) 2009. [DOI: 10.1016/s0035-3787(09)70019-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
Denier C, Tertian G, Ribrag V, Lozeron P, Bilhou-Nabera C, Lazure T, Abbed K, Lacroix C, Adams D. Multifocal deficits due to leukemic meningoradiculitis in chronic lymphocytic leukemia. J Neurol Sci 2008; 277:130-2. [PMID: 19100998 DOI: 10.1016/j.jns.2008.11.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2008] [Revised: 10/22/2008] [Accepted: 11/03/2008] [Indexed: 11/28/2022]
Abstract
Symptomatic nervous system leukemic infiltration is rarely observed in CLL. Various clinical manifestations including headache, confusion, cranial nerve palsies, focal central deficits and peripheral neuropathies have been seldom reported, occurring in less than 1% of patients. We report herein 2 CLL patients with unusual clinical presentations of nervous system invasion. They presented multiple progressive peripheral deficits due to meningoradiculitis. In both, CSF immunophenotyping analysis identified a majority of T cells (>90%), and less than 10% of B-CLL cells expressing CD5, CD19 and CD20. Our analyses revealed the transformation of CLL into an aggressive B-cell lymphoma in one case (Richter's syndrome). A post mortem study showed massive infiltration of cranial nerves and spinal roots by large B lymphomatous cells. In the other case, CNS oriented chemotherapy led to remission and total neurological recovery. In practice, the etiological diagnosis of neurological deficits in CLL patients is difficult. CSF analysis may be useful, requiring viral PCR, repeated cytological studies and immunophenotyping analysis. Although rare, leptomeningeal leukemic localization has to be discussed, even in the absence of overt Richter syndrome, and may require an early therapeutic test.
Collapse
Affiliation(s)
- C Denier
- Services de Neurologie, Centre Hospitalier Universitaire de Bicêtre, Assistance Publique des Hôpitaux de Paris, Université Paris-Sud 11, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Wargon I, Lacour MC, Adams D, Denier C. A small deep infarct revealing leukoencephalopathy, calcifications and cysts in an adult patient. J Neurol Neurosurg Psychiatry 2008; 79:224-5. [PMID: 18202216 DOI: 10.1136/jnnp.2007.125302] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
39
|
Denier C, Bouteredjiret T, Dreyfus M, Lacroix C, Adams D. Late and Fatal Deterioration of an Intracerebral Hemorrhage Attributable to the Onset of a High Titer of Acquired Factor V Inhibitor. Eur Neurol 2008; 60:206-7. [DOI: 10.1159/000148692] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2007] [Accepted: 11/27/2007] [Indexed: 11/19/2022]
|
40
|
Denier C, Orgibet A, Roffi F, Jouvent E, Buhl C, Niel F, Boespflug-Tanguy O, Said G, Ducreux D. Adult-onset vanishing white matter leukoencephalopathy presenting as psychosis. Neurology 2007; 68:1538-9. [PMID: 17470759 DOI: 10.1212/01.wnl.0000260701.76868.44] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- C Denier
- Department of Neurology, Hôpital de Bicêtre, Assistance-Publique-Hôpitaux de Paris, Universite Paris XI, Le Kremlin-Bicêtre, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Denier C, Bourhis JH, Lacroix C, Koscielny S, Bosq J, Sigal R, Said G, Adams D. Spectrum and prognosis of neurologic complications after hematopoietic transplantation. Neurology 2006; 67:1990-7. [PMID: 17159106 DOI: 10.1212/01.wnl.0000247038.43228.17] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To describe the neurologic complications after hematopoietic progenitor cell transplantation (HPCT) in order to design rules for their management. METHODS We reviewed 361 consecutive patients over 6 years, including 245 autologous and 116 allogeneic HPCT recipients for hematologic malignancies (87%) and solid cancers (13%). RESULTS Fifty-seven patients developed 65 symptomatic neurologic complications (16%), with a higher incidence in allogeneic than in autologous HPCT recipients (p = 0.01) and in chronic myelogenous leukemia (42%) than in Hodgkin disease (2.5%) (p < 0.001). CNS infections (4.2%) were the main complications, marked by an early onset (within the first 4 months) after HPCT (87%), diagnostic difficulties, and a high mortality rate (47%). They mainly included cerebral toxoplasmosis, fungal infections, and viral encephalitis. Their incidence was markedly higher in allogeneic than in autologous HPCT recipients (p = 0.002). However, two CD34(+) selected autologous HPCT recipients developed cerebral toxoplasmosis. Other CNS complications included recurrent tumors (3.6%), metabolic encephalopathies (2.8%), and cerebrovascular events (1.7%). Seizures occurred in 5% of patients, most often associated with cerebral lesions. Peripheral nervous system manifestations occurred in 3.3%. Twenty-one patients (5.8%) died directly of neurologic complications. The 4-year probability of survival was markedly lower in the case of neurologic events than in the absence thereof (12% vs 58%, p < 0.0001). CONCLUSIONS Severe neurologic complications after hematopoietic progenitor cell transplantations are common, vary according to the underlying disease and type of transplantation, and are associated with poor survival rates. Better prophylactic protocols and therapy for CNS infections are required in future studies.
Collapse
Affiliation(s)
- C Denier
- Department of Neurology, Bicêtre Hospital AP-HP, France
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Liberatore M, Denier C, Fillard P, Petit-Lacour MC, Benoudiba F, Lasjaunias P, Ducreux D. Suivi évolutif d’une myelinolyse centro-pontique en IRM de tenseur de diffusion et de tracking de fibres. J Neuroradiol 2006; 33:189-93. [PMID: 16840962 DOI: 10.1016/s0150-9861(06)77258-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVES To illustrate the value of diffusion tensor imaging and tractography in the diagnosis and follow-up of central pontine myelinolysis. CASE REPORT We report a case of central pontine myelinolysis in a 29 year old woman, also anorexic, studied using MR Diffusion Tensor Imaging (DTI) and Fibre Tracking (FT) focused on the pons, and compared with the studies of 5 normal volunteers. Tractography showed a swollen aspect of the right corticospinal fiber tract correlating with mild left lower extremity deficit at clinical evaluation. The pontine fibers were posteriorly displaced but intact. The sensory tracts were also intact. Apparent Diffusion Coefficient values were increased and Fractional Anisotropy was decreased in the lesions. Follow up imaging showed persistent abnormal ADC and FA values in the pons although the left cortico-spinal tract returned to normal, consistent with the clinical outcome. CONCLUSION Diffusion Tensor Imaging MR and Fiber tractography are a new method to analyse white matter tracts. It can be used to prospectively evaluate the location of white matter tract lesions at the acute phase of central pontine myelinolysis and follow up.
Collapse
Affiliation(s)
- M Liberatore
- Service de Neuroradiologie, CHU de Bicêtre, Université Paris XI, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre
| | | | | | | | | | | | | |
Collapse
|
43
|
Denier C, Lozeron P, Adams D, Decaudin D, Isnard-Grivaux F, Lacroix C, Said G. Multifocal neuropathy due to plasma cell infiltration of peripheral nerves in multiple myeloma. Neurology 2006; 66:917-8. [PMID: 16567713 DOI: 10.1212/01.wnl.0000203345.29020.db] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Patients with multiple myeloma (MM) can manifest a variety of neurologic complications. The authors report two patients who had development of a multifocal neuropathy related to infiltration of peripheral nerves by malignant plasma cells as the only manifestation of a relapse of MM, which was considered in full remission.
Collapse
Affiliation(s)
- C Denier
- Department of Neurology, University Paris XI, Hopital de Bicêtre, Paris, France
| | | | | | | | | | | | | |
Collapse
|
44
|
Roffi F, Denier C, Adams D, Corruble E, Ducreux D. P-13 - Imagerie multimodale du syndrome de « vanishing white matter » : à propos d’un cas. J Neuroradiol 2006. [DOI: 10.1016/s0150-9861(06)77196-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
45
|
Bergametti F, Denier C, Labauge P, Arnoult M, Boetto S, Clanet M, Coubes P, Echenne B, Ibrahim R, Irthum B, Jacquet G, Lonjon M, Moreau JJ, Neau JP, Parker F, Tremoulet M, Tournier-Lasserve E. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 2005; 76:42-51. [PMID: 15543491 PMCID: PMC1196432 DOI: 10.1086/426952] [Citation(s) in RCA: 319] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2004] [Accepted: 10/11/2004] [Indexed: 11/03/2022] Open
Abstract
Cerebral cavernous malformations (CCMs) are hamartomatous vascular malformations characterized by abnormally enlarged capillary cavities without intervening brain parenchyma. They cause seizures and cerebral hemorrhages, which can result in focal neurological deficits. Three CCM loci have been mapped, and loss-of-function mutations were identified in the KRIT1 (CCM1) and MGC4607 (CCM2) genes. We report herein the identification of PDCD10 (programmed cell death 10) as the CCM3 gene. The CCM3 locus has been previously mapped to 3q26-27 within a 22-cM interval that is bracketed by D3S1763 and D3S1262. We hypothesized that genomic deletions might occur at the CCM3 locus, as reported previously to occur at the CCM2 locus. Through high-density microsatellite genotyping of 20 families, we identified, in one family, null alleles that resulted from a deletion within a 4-Mb interval flanked by markers D3S3668 and D3S1614. This de novo deletion encompassed D3S1763, which strongly suggests that the CCM3 gene lies within a 970-kb region bracketed by D3S1763 and D3S1614. Six additional distinct deleterious mutations within PDCD10, one of the five known genes mapped within this interval, were identified in seven families. Three of these mutations were nonsense mutations, and two led to an aberrant splicing of exon 9, with a frameshift and a longer open reading frame within exon 10. The last of the six mutations led to an aberrant splicing of exon 5, without frameshift. Three of these mutations occurred de novo. All of them cosegregated with the disease in the families and were not observed in 200 control chromosomes. PDCD10, also called "TFAR15," had been initially identified through a screening for genes differentially expressed during the induction of apoptosis in the TF-1 premyeloid cell line. It is highly conserved in both vertebrates and invertebrates. Its implication in cerebral cavernous malformations strongly suggests that it is a new player in vascular morphogenesis and/or remodeling.
Collapse
Affiliation(s)
- F. Bergametti
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - C. Denier
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - P. Labauge
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - M. Arnoult
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - S. Boetto
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - M. Clanet
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - P. Coubes
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - B. Echenne
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - R. Ibrahim
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - B. Irthum
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - G. Jacquet
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - M. Lonjon
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - J. J. Moreau
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - J. P. Neau
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - F. Parker
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - M. Tremoulet
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | - E. Tournier-Lasserve
- INSERM E365, Faculté de Médecine Lariboisière, and Laboratoire de Cytogénétique et Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris; Service de Neurologie, Nîmes, France; Services des Neurochirurgie and Neurologie, Toulouse; Services des Neurochirurgie and Neuropédiatrie, Montpellier, France; Service de Neurochirurgie, Nantes, France; Service de Neurochirurgie, Limoges, France; Service de Neurochirurgie, Besançon, France; Service de Neurochirurgie, Nice; Service de Neurochirurgie, Poitiers, France; and Service de Neurochirurgie, Kremlin-Bicêtre, France
| | | |
Collapse
|
46
|
Nyasse B, Ngantchou I, Tchana EM, Sonké B, Denier C, Fontaine C. Inhibition of both Trypanosoma brucei bloodstream form and related glycolytic enzymes by a new kolavic acid derivative isolated from Entada abyssinica. Pharmazie 2004; 59:873-5. [PMID: 15587590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
A new kolavic acid derivative known from spectroscopic analyses as monomethyl ester-15-kolavic acid was isolated from the stem bark of Entada abyssinica, a plant traditionally used in West and East Africa for the management of sleeping sickness. The new derivative showed a strong and selective inhibitory activity on the GAPDH enzyme of Trypanosoma brucei with an IC50 value of 0.012 mM.
Collapse
Affiliation(s)
- B Nyasse
- Laboratory of Bio-organic and Medicinal Chemistry, Department of Organic Chemistry, Faculty of Science, University of Yaounde I, Cameroon.
| | | | | | | | | | | |
Collapse
|
47
|
Nyasse B, Nono J, Sonke B, Denier C, Fontaine C. Trypanocidal activity of bergenin, the major constituent of Flueggea virosa, on Trypanosoma brucei. Pharmazie 2004; 59:492-4. [PMID: 15248469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
The presence of bergenin in substantial amounts in the methanol leaves extract of Flueggea virosa (Euphorbiaceae) was established as a strong chemotaxomic point of differentiation between Flueggea virosa and Securinega virosa. Bergenin showed an inhibitory effect on the growth of the bloodstream form of Trypanosoma brucei with an IC50 value of 1 microM.
Collapse
Affiliation(s)
- B Nyasse
- Department of Organic Chemistry, Faculty of Science, Higher Teachers Training College, University of Yaoundé I, Cameroon.
| | | | | | | | | |
Collapse
|
48
|
Denier C, Goutagny S, Labauge P, Krivosic V, Arnoult M, Cousin A, Benabid AL, Comoy J, Frerebeau P, Gilbert B, Houtteville JP, Jan M, Lapierre F, Loiseau H, Menei P, Mercier P, Moreau JJ, Nivelon-Chevallier A, Parker F, Redondo AM, Scarabin JM, Tremoulet M, Zerah M, Maciazek J, Tournier-Lasserve E. Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet 2004; 74:326-37. [PMID: 14740320 PMCID: PMC1181930 DOI: 10.1086/381718] [Citation(s) in RCA: 187] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2003] [Accepted: 11/25/2003] [Indexed: 11/04/2022] Open
Abstract
Cerebral cavernous malformations (CCM) are hamartomatous vascular malformations characterized by abnormally enlarged capillary cavities without intervening brain parenchyma. They cause seizures and focal neurological deficits due to cerebral hemorrhages. CCM loci have already been assigned to chromosomes 7q (CCM1), 7p (CCM2), and 3q (CCM3) and have been identified in 40%, 20%, and 40%, respectively, of families with CCM. Loss-of-function mutations have been identified in CCM1/KRIT1, the sole CCM gene identified to date. We report here the identification of MGC4607 as the CCM2 gene. We first reduced the size of the CCM2 interval from 22 cM to 7.5 cM by genetic linkage analysis. We then hypothesized that large deletions might be involved in the disorder, as already reported in other hamartomatous conditions, such as tuberous sclerosis or neurofibromatosis. We performed a high-density microsatellite genotyping of this 7.5-cM interval to search for putative null alleles in 30 unrelated families, and we identified, in 2 unrelated families, null alleles that were the result of deletions within a 350-kb interval flanked by markers D7S478 and D7S621. Additional microsatellite and single-nucleotide polymorphism genotyping showed that these two distinct deletions overlapped and that both of the two deleted the first exon of MGC4607, a known gene of unknown function. In both families, one of the two MGC4607 transcripts was not detected. We then identified eight additional point mutations within MGC4607 in eight of the remaining families. One of them led to the alteration of the initiation codon and five of them to a premature termination codon, including one nonsense, one frameshift, and three splice-site mutations. All these mutations cosegregated with the disease in the families and were not observed in 192 control chromosomes. MGC4607 is so far unrelated to any known gene family. Its implication in CCMs strongly suggests that it is a new player in vascular morphogenesis.
Collapse
Affiliation(s)
- C. Denier
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - S. Goutagny
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - P. Labauge
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - V. Krivosic
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - M Arnoult
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - A. Cousin
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - A. L. Benabid
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - J. Comoy
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - P. Frerebeau
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - B. Gilbert
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - J. P. Houtteville
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - M. Jan
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - F. Lapierre
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - H. Loiseau
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - P. Menei
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - P. Mercier
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - J. J. Moreau
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - A. Nivelon-Chevallier
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - F. Parker
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - A. M. Redondo
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - J. M. Scarabin
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - M. Tremoulet
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - M. Zerah
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - J. Maciazek
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | - E. Tournier-Lasserve
- INSERM E365, Faculté de Médecine Lariboisière,Laboratoire de Cytogénétique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, and Service de Neurochirurgie, CHU de Necker-Enfants Malades, Paris; Service de Neurologie, CHU Montpellier Nîmes, Nîmes, France; Service de Neurochirurgie, CHU de Grenoble, Grenoble, France; Service de Neurochirurgie, CHU de Kremlin-Bicêtre, Kremlin-Bicêtre, France; Service de Neurochirurgie CHU de Montpellier, Montpellier, France; Génétique, CHU de Limoges, and Service de Neurochirurgie, CHU de Limoges, Limoges, France; Service de Neurochirurgie, CHU de Caen, Caen, France; Service de Neurochirurgie, CHU de Tours, Tours; Service de Neurochirurgie, CHU de Poitiers, Poitiers, France; Service de Neurochirurgie, CHU de Toulouse, Toulouse; Service de Neurochirurgie, CHU de Angers, Angers, France; Génétique, CHU de Dijon, Dijon; Service de Neurochirurgie, Hôpital Beaujon, Clichy, France; and Service de Neurochirurgie, CHU de Rennes, Rennes, France
| | | |
Collapse
|
49
|
Denier C, Gasc JM, Chapon F, Domenga V, Lescoat C, Joutel A, Tournier-Lasserve E. Krit1/cerebral cavernous malformation 1 mRNA is preferentially expressed in neurons and epithelial cells in embryo and adult. Mech Dev 2002; 117:363-7. [PMID: 12204286 DOI: 10.1016/s0925-4773(02)00209-5] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Cavernous malformations are capillaro-venous lesions mostly located within the central nervous system (CCM/OMIM#116860) and occasionally within the skin and/or retina. They occur as a sporadic or hereditary condition. Three CCM loci have been mapped, and the sole gene identified so far, CCM1, has been shown to encode KRIT1, a protein of unknown function. In an attempt to get some insight on the relationship between KRIT1 mutations and CCM lesions, we investigated Krit1 mRNA expression during mouse development from E7.5 to E20.5 and in adult tissues, of both mouse and human origin. A ubiquitous Krit1 mRNA expression was detected from E7.5 up to E9.5. Then, it became progressively restricted from E10.5 to E12.5, to become detectable later essentially in the nervous system and various epithelia. Strong labelling was observed in neurons in the brain, cerebellum, spinal cord, retina and dorsal root ganglia. In epithelia, Krit1 mRNA expression was detected in differentiating epidermal, digestive, respiratory, uterine and urinary epithelia. A similar pattern of expression persisted in mouse and man adult nervous system and epithelia. Unexpectedly, in vascular tissues, expression of Krit1 was detected only in large blood vessels of the embryo.
Collapse
Affiliation(s)
- C Denier
- INSERM EMI 99-21, Faculté de Médecine Lariboisière, 10, avenue de Verdun, 75010 Paris, France
| | | | | | | | | | | | | |
Collapse
|
50
|
Nyasse B, Nkwengoua E, Sondengam B, Denier C, Willson M. Modified berberine and protoberberines from Enantia chlorantha as potential inhibitors of Trypanosoma brucei. Pharmazie 2002; 57:358-61. [PMID: 12116870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Phytochemical study of the stem bark of Enantia chlorantha resulted in the isolation of two protoberberines 1 and 2. These alkaloids as well as commercially available berberine were modified chemically and tested in vitro against Typanosoma brucei proliferation as well as on three targeted glycolytic enzymes. The inhibitory activities observed were in the range of 20 microM (ED50 values).
Collapse
Affiliation(s)
- B Nyasse
- Department of Organic Chemistry, Faculty of Science, University of Yaoundé I, Cameroon.
| | | | | | | | | |
Collapse
|